Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03616418
Other study ID # abilities
Secondary ID
Status Completed
Phase
First received
Last updated
Start date January 1, 2017
Est. completion date August 1, 2021

Study information

Verified date December 2021
Source Shanghai 10th People's Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

Peripheral arterial disease (PAD) is a common clinical manifestation of the systemic atherosclerotic process, and the ankle brachial index (ABI) is an ideal tool to diagnose PAD. The association between high serum uric acid levels (SUA) and arterial stiffness as well as endothelial dysfunction has been demonstrated in humans and uric acid has been suggested to be an important modulator of the inflammatory process. It has also been confirmed by clinical studies. Currently, there have been few long term follow up studies focused on the whether serum uric acid levels combined with ankle brachial index can improve prediction all cause mortality and cardiovascular mortality,especially in China population.Therefore, the aim of this study was to elucidate whether ABIcombined with SUA can improve prediction all cause mortality and cardiovascular mortality in the elderly China population independently of the traditional Framingham Risk Score.


Description:

This study is a prospective community-based cohort study, which is aimed to investigate the prognostic factors, including conventional cardiovascular risk factors and measure ABI,SUA,asymptomatic target organ damage, for mortality and cardiovascular diseases. All population were separated into ABI ≤0.50,0.51


Recruitment information / eligibility

Status Completed
Enrollment 3026
Est. completion date August 1, 2021
Est. primary completion date August 1, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 65 Years and older
Eligibility Inclusion Criteria: 1. age=65 years old 2. Shanghai residents 3. Sign informed consent Exclusion Criteria: 1. serious heart disease (NYHA>IV) or end stage renal disease (CKD > 4) 2. cancer and life expectancy was less than 5 years 3. Severe congestive heart failure and Severe renal failure patients 4. Participants had other diseases that required withdrawal from the clinical trial 5. Patients are reluctant to participate in clinical research 6. The patient violated the experimental protocol 7. Clinical diagnosis of Alzheimer's Disease

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
antiplatelet drugs;statins;antihypertensive drugs


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Shanghai 10th People's Hospital

Outcome

Type Measure Description Time frame Safety issue
Primary all cause mortality and cardiovascular mortality Cardiovascular events definitions: Hospitalized myocardial infarction was classified as definite or probable based on chest pain symptoms, cardiac enzyme levels, and electrocardiographic findings, or angioplasty28. Coronary heart disease was determined to be present if there was (1) electrocardiographic (ECG) evidence of a prior myocardial infarction, (2) prior coronary artery bypass surgery or angioplasty, (3) Coronary angiography show coronary heart disease, (4) have symptoms of angina and ECG revealed myocardial ischemia performance or laboratory tests showed cardiac enzymes increased and exclude other types of disease, (5) a self-reported history of a physician-diagnosed heart attack 29. CHD death was classified "definite" based on chest pain symptoms, hospital records, and medical history. From August 2018 to August 2020
See also
  Status Clinical Trial Phase
Completed NCT04811547 - Ankle-Brachial Index to Predicte All-Cause and Cardiovascular Mortality in Framingham Risk Score Patients
Recruiting NCT03521739 - Association of Synchronous Four-limb blOod pRessure and Pulse Wave velocIty With Cardiovascular Events